There were 301 NFE2L2 mutations (MUs, 3.0%) in the OrigiMed cohort with esophageal carcinoma (ESCA, 12.1%) ranking first followed by thyroid carcinoma (6.3%), gallbladder carcinoma (5.4%) and NSCLC (4.7%) (Fig. 2 A and B). This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.